Akeso (9926 HK): Synthetic Expert Call Transcript (14 Oct 2026)
Ivonescimab’s head-to-head overall survival (OS) victory over Keytruda in HARMONi-2 (median OS 30.8 months vs 22.6 months, HR 0.73) validates the...
10 Views
Salubris (信立泰) A+H Pre-IPO: 1H26 Results Update
Salubris is seeking an A+H listing. In this note we update the company's fundamentals and business development since our last coverage.
23 Views
Sirnaomics Ltd.: The RNAimmune Money Is In, and the FDA Has Answered in Writing on STP705
VASRO has published an update report on Sirnaomics Ltd. (HKEX: 2257) following the company’s announcement of 6 October 2026 and the FDA’s written...
16 Views
Aequitas: Akeso Inc Placement Past Deals Have Been Weak but Current Raise Is Less Opportunistic
Akeso is looking to raise around US$250m in a primary offering. In this note, we talk about the deal dynamics and run the deal through our ECM...
70 Views
Wuxi Biologics (2269 HK) Placement - Thought on Valuation and the Outlook
After WuXi Bio's shares experienced significant surge this year, valuation may have partially overdrawn the future growth expectations. The...
97 Views